The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Join the Hive!

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Over 330,000 Congolese migrants at risk after mass deportations from Angola – UN rights chief

Digital democracy: a Swiss view on digital trust

European Border and Coast Guard: 10 000-strong standing corps by 2027

Nike’s hands-free shoe is a step forward for inclusive clothing

Coronaviruses: the truth against the myths

‘Act now with ambition and urgency’ to tackle the world’s ‘grave climate emergency’, UN chief urges UAE meeting

Inclusion, equality a must for ‘long-lasting peace and sustainable development’, UN official tells high-level event in Baku

Medical ethics in the age of the social media influencers

Wide-ranging reforms needed to ensure Italy’s economic recovery

Future EU-UK Partnership: European Commission takes first step to launch negotiations with the United Kingdom

Sydney is choking on record levels of smog – and the bushfire season is just getting started

Mobile technology, a necessary pearl in developing countries

Medicines from the sky: how drones can save lives

New UN book club helps children deal with global issues

Iraq needs support to ‘leave violent past behind’, says UN envoy as Security Council extends UN mission for one year

Investing in education and skills can improve the health of both humans and planet. Here’s why

Business leaders join UN to rev up sustainable development investments

Canada and EU officially sign the trade agreement that could open-up the road to TTIP

Burkina Faso: Dozens killed in clashes, UN chief condemns attacks

Visa Facilitation and Readmission: the European Union and Belarus sign agreements

These cities score an ‘A’ for environmental action – but hundreds more are falling behind

New seat projections for the next European Parliament

Mental health in a pandemic: what to do to ease the burden on people with disabilities?

A Sting Exclusive: “Infrastructure can lay the groundwork for the Sustainable Development Goals” by Mr Fulai Sheng, UN Environment Senior Economist

Measuring consumer confidence isn’t useful anymore. Here’s what we should do instead

Health Education, is it a necessity?

EU boosts sustainable cocoa production in Côte d’Ivoire, Ghana and Cameroon

Returning to free movement across borders is of utmost importance

The Chinese film boom luring Hollywood’s stars

Human trafficking: stronger measures to protect women, children and migrants

Coronavirus: Commission proposes to provide €81.4 billion in financial support for 15 Member States under SURE

UN condemns Syrian ‘war on children’ as up to 30 reportedly killed in clashes

MEPs demand Bulgaria’s and Romania’s swift accession to Schengen area

Inflation and interest rates indicate urgent need for action

A Sting Exclusive: “Asia-Pacific response to COVID-19 and climate emergency must build a resilient and sustainable future”, by the United Nations Under-Secretary-General

“Unequivocal support” for the people of Bulgaria in their legitimate demands

Commission threatens Chinese firms with trade penalties

Young health workforce – a core of effective primary healthcare?

‘Countless opportunities’ for new people-centred workplace, but ‘decisive action’ critical

If airlines were a country they’d be one of the world’s top 10 greenhouse gas emitters

Belgium: Youth Forum takes legal step to ban unpaid internships

Sustainable Development Summit: ‘We must step up our efforts – now’, Guterres declares

Aid convoy for north-east Syria postponed over security concerns – UN relief chief

EU Youth Report casts stark light on life for young Europeans

Coronavirus: the Commission approves third contract to ensure access to a potential vaccine

EU Copyright Directive: Google News threatens to leave Europe while media startups increasingly worry

Corruption thwarts attempts to build a better world and ‘must be fought by all, for all’

India is now the world’s 5th largest economy

This tool shows you which cities will flood as ice sheets melt

Turkey: Extension of EU humanitarian programmes supporting 1.7 million refugees receives green light

Europe faces economic turmoil as Italy gets closer to the Excessive Debt Procedure

This is why obesity is classified as a type of malnutrition

These 5 start-ups are shaping the future of Africa’s cities

4 solutions for reducing emissions from industrial clusters

Community Manager – 1289

How privacy tech is redefining the data economy

The Brits are not an exception and that’s why they voted to leave

3 principles to reinforce digital trust in supply chains

Future of Insurance Claims in Focus at Fourth Annual Connected Claims Europe Summit

At this ‘critical moment’, UN chief urges anti-corruption conference to adopt united front

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s